Galderma backs new evidence for Sculptra and Restylane in fast-evolving patient demand segments

Read how Galderma’s new interim data could influence aesthetic treatment planning in menopause and GLP-1-related volume loss.

Read how Galderma’s new interim data could influence aesthetic treatment planning in menopause and GLP-1-related volume loss.

Explore how Galderma’s Wake Up To Restylane strategy and new IMCAS data could reshape aesthetic practice and hyaluronic acid filler adoption.